Ananda Mohan Chakraborty¹, Poonam Kumari², Gurjeet Kaur³, Rimesh Pal⁴, Soham Mukherjee⁴, Divya Dahiya⁵, Aswini Sood⁶, Pinaki Dutta⁷ and Sanjay Kumar Bhadada⁸*

¹Senior Resident, Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
²Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
³Young Scientist. Department of Renal transplant and Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India
⁴Assistant Professor, Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
⁵Associate Professor, Department of Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
⁶Professor, Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
⁷Professor, Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
⁸Professor and Head, Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

*Corresponding Author: Sanjay Kumar Bhadada, Professor and Head, Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Received: November 27, 2024; Published: January 30, 2025

Abstract

Introduction: Despite heterogeneity, the most consistent presentation of multiple endocrine neoplasia (MEN) is primary hyperparathyroidism (PHPT) seen in almost 100% of cases in MEN-1 and nearly 30% in MEN-2A. This retrospective study was planned to compare the demography, clinical manifestations, management, and outcome of sporadic PHPT (s-PHPT) and multiple endocrine neoplasia (m-PHPT) patients.

Methodology: This was a registry-based (www.indianphptregistry.com) retrospective cohort study from a tertiary care hospital in North India. In this study, medical records, and clinical data of s-PHPT patients and genetically proven and clinically suspected m-PHPT patients were analyzed.

Result: A total of 616 PHPT patients have been registered in the electronic registry, and 72 (11.68%) patients had m-PHPT. The mean age of s-PHPT and m-PHPT patients was 43.4 ± 14.3 and 35.8 ± 13.5 years (p < 0.05) respectively. The multiglandular disease was common in m-PHPT (40.2%) compared to s-PHPT (6%). Both s-PHPT and m-PHPT had comparable mean calcium, mean phosphate, and median PTH but the median 25(OH) vitamin D (25OHD) level was more in s-PHPT as compared to m-PHPT. Median post-surgery falls in parathyroid hormone (PTH), and calcium were more in the patients of s-PHPT compared to m-PHPT 84.8% vs 46.7% and 23.4% vs 16.6% respectively (p < 0.05).

Conclusion: This study showed that m-PHPT patients presented at a young age had more asymptomatic presentation and multiglandular disease without significant differences in serum biochemistry. Percent fall in PTH and calcium were more in s-PHPT patients in the post-surgery period with less incidence of recurrent and persistent disease.

 Keywords: Primary Hyperparathyroidism; Multiple Endocrine Neoplasia; MEN-1; Hypercalcemia

References

1. Melton LJ. “Epidemiology of primary hyperparathyroidism”. Journal of Bone and Mineral ResearchS2 (2009): S25-S30.
2. Lundgren E. “Primary Hyperparathyroidism of Postmenopausal Women”. Upsala Journal of Medical Sciences 2 (1999): 87-130.
3. Melton LJ. “Epidemiology of primary hyperparathyroidism”. Journal of Bone and Mineral ResearchS2 (2009): S25-S30.
4. Brandi ML., et al. “CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2”. The Journal of Clinical Endocrinology and Metabolism12 (2001): 5658-5671.
5. Takami H., et al. “Familial hyperparathyroidism”. Biomedicine and Pharmacotherapy 54 (2000): 21s-24s.
6. Huang SM., et al. “Familial Hyperparathyroidism without Multiple Endocrine Neoplasia”. World Journal of Surgery1 (1997): 22-29.
7. BRANDI ML., et al. “Familial Multiple Endocrine Neoplasia Type I: A New Look at Pathophysiology”. Endocrine Review4 (1987): 391-405.
8. Lundgren E., et al. “Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women”. Surgery 3 (1997): 287-294.
9. Lips C., et al. “Clinical Screening as Compared with DNA Analysis in Families with Multiple Endocrine Neoplasia Type 2A”. New England Journal of Medicine 13 (1994): 828-835.
10. Uchino S., et al. “Screening of the Men1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors”. Cancer Research19 (2000): 5553-5557.
11. Langer P., et al. “Prevalence of multiple endocrine neoplasia type 1 in young patients with apparently sporadic primary hyperparathyroidism or pancreaticoduodenal endocrine tumours”. British Journal of Surgery12 (2003): 1599-1603.
12. Brandi ML., et al. “CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2”. The Journal of Clinical Endocrinology and Metabolism12 (2001): 5658-5671.
13. Thakker R V., et al. “Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)”. The Journal of Clinical Endocrinology and Metabolism9 (2012): 2990-3011.
14. Twigt BA., et al. “Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperative workup, operative strategy and follow-up”. Orphanet Journal of Rare Diseases1 (2013): 50.
15. Eller-Vainicher C., et al. “Sporadic and MEN1-Related Primary Hyperparathyroidism: Differences in Clinical Expression and Severity”. Journal of Bone and Mineral Research8 (2009): 1404-1410.
16. Bhadada SK., et al. “Primary hyperparathyroidism: insights from the Indian PHPT registry”. Journal of Bone and Mineral Metabolism2 (2018): 238-245.
17. Kumari P., et al. “Comparison of Profile of Primary Hyperparathyroidism With and Without Type 2 Diabetes Mellitus: Retrospective Analysis From the Indian Primary Hyperparathyroidism Registry”. Endocrine Practice1 (2022): 96-101.
18. Bhadada S., et al. “Influence of age and gender on presentation of symptomatic primary hyperparathyroidism”. Journal of Postgraduate Medicine 2 (2012): 107.
19. Starker LF., et al. “Frequent Germ-Line Mutations of the MEN1, CASR, and HRPT2/CDC73 Genes in Young Patients with Clinically Non-familial Primary Hyperparathyroidism”. Horm Cancer1-2 (2012): 44-51.
20. Kaur G., et al. “Multilevel Annotation of Germline <scp> MEN1 </scp> Variants of Synonymous, Nonsynonymous, and Uncertain Significance in Indian Patients With Sporadic Primary Hyperparathyroidism”. Journal of Bone and Mineral Research10 (2022): 1860-1875.
21. Moffett JM and Suliburk J. “Parathyroid Autotransplantation”. Endocrine Practice 17 (2011): 83-89.

Citation

Citation: Sanjay Kumar Bhadada., et al. “Comparison between Sporadic Primary Hyperparathyroidism and Multiple Endocrine Neoplasia Associated Primary Hyperparathyroidism: Retrospective Analysis of Indian PHPT Registry”.Acta Scientific Medical Sciences 9.2 (2025): 159-166.

Copyright

Copyright: © 2025 Sanjay Kumar Bhadada., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.